Keytruda

Active substance

Pembrolizumab

Holder

MSD Belgium BV/SRL

Statut

closed

Indication

for the adjuvant treatment of renal cell carcinoma patients with intermediate-high risk and high risk of recurrence after nephrectomy.

Public documents

Approbation

Information for the patient

Informed consent

Last update

15/04/2025
Last updated on